YS Biopharma Co., Ltd. (YS)
(Real Time Quote from BATS)
$0.99 USD
+0.03 (3.13%)
Updated May 21, 2024 10:46 AM ET
4-Sell of 5 4
C Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
YS 0.99 +0.03(3.13%)
Will YS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for YS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for YS
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
YS Biopharma appoints Dave Chenn as interim CEO
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
YS Biopharma gets additional 180 days extension from Nasdaq
YS Biopharma granted additional 180 day extension by Nasdaq to regain compliance